The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Merck Serono; Otsuka
Consulting or Advisory Role - Bayer; MSD; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Naomi Kiyota
Honoraria - Eisai
Research Funding - Boehringer Ingelheim (Inst); Eisai (Inst); Ono Pharmaceutical (Inst)
 
Tomoya Yokota
Honoraria - Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Merck Serono; Niphix; Niphix; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Serono; Merck Serono
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); MSD (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Sanofi (Inst)
 
Yasuhisa Hasegawa
No Relationships to Disclose
 
Kei Muro
Honoraria - Chugai Pharma; Takeda; Yakult Honsha
Consulting or Advisory Role - Takeda
 
Shunji Takahashi
Honoraria - Merck Serono
 
Takuma Onoe
No Relationships to Disclose
 
Akihiro Homma
No Relationships to Disclose
 
Jun Taguchi
No Relationships to Disclose
 
Masami Suzuki
No Relationships to Disclose
 
Koichi Minato
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst)
 
Katsunari Yane
No Relationships to Disclose
 
Shinya Ueda
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ken Saijo
No Relationships to Disclose
 
Takeharu Yamanaka
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda